Aratana Therapeutics (NASDAQ: PETX), a Kansas City, Kansas-based pet therapeutics company, received a $40m credit facility.
The financing refinanced a $15m loan facility, with the additional $25m to be used to support the company’s continued growth.
Led by Steven St. Peter, M.D. Founder, President & CEO, Aratana Therapeutics focuses on the licensing, development and commercialization of biopharmaceutical products for companion animals. Its pipeline currently includes treatments for pain management, inappetence, allergies, cancer, viral diseases and other conditions.